Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q1

4574.TEDINET S100QQ1J
Period2023-01-01 → 2023-03-31
Filed2023-05-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥1.2bn2023-01-01 → 2023-03-31Cons.Net sales
Revenue¥5.0bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥621m2022-01-01 → 2022-03-31Cons.Net sales
Operating income−¥155m2023-01-01 → 2023-03-31Cons.Operating income
Operating income−¥1.7bn2022-01-01 → 2022-03-31Cons.Operating income
Ordinary income−¥242m2023-01-01 → 2023-03-31Cons.Ordinary income
Ordinary income−¥3.4bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.7bn2022-01-01 → 2022-03-31Cons.Ordinary income
Profit before tax−¥242m2023-01-01 → 2023-03-31Cons.Income before income taxes
Profit before tax−¥1.7bn2022-01-01 → 2022-03-31Cons.Income before income taxes
Net income (owners)−¥243m2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.7bn2022-01-01 → 2022-03-31Cons.Profit loss attributable to owners of parent
Net income−¥243m2023-01-01 → 2023-03-31Cons.Profit loss
Net income−¥1.7bn2022-01-01 → 2022-03-31Cons.Profit loss
Total assets¥14.4bnat 2023-03-31Cons.Assets
Total assets¥15.0bnat 2022-12-31Cons.Assets
Total assets¥19.7bnat 2022-03-31Cons.Total assets (5-year summary)
Total liabilities¥6.5bnat 2023-03-31Cons.Liabilities
Total liabilities¥7.0bnat 2022-12-31Cons.Liabilities
Net assets / equity¥7.9bnat 2023-03-31Cons.Net assets
Net assets / equity¥8.0bnat 2022-12-31Cons.Net assets
Net assets / equity¥11.1bnat 2022-03-31Cons.Net assets (5-year summary)
Cash and deposits¥3.1bnat 2023-03-31Cons.Cash and deposits
Cash and deposits¥3.1bnat 2022-12-31Cons.Cash and deposits
EPS (basic)¥-5.592023-01-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-112.262022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-40.132022-01-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio54.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio53.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio56.4%at 2022-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥241m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥259m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥259m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-03-31−¥124m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue2023-01-01 → 2023-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue external2023-01-01 → 2023-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentsegment profit2023-01-01 → 2023-03-31−¥5m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥906m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥906m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-03-31¥215m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-03-31¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-03-31¥1.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-03-31¥85m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-03-31−¥360m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-03-31¥39m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-03-31¥39m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-03-31−¥1.3bn
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue2022-01-01 → 2022-03-31¥2m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue external2022-01-01 → 2022-03-31¥2m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentsegment profit2022-01-01 → 2022-03-31−¥6m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-03-31¥579m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-03-31¥579m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-03-31¥13m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-03-31¥621m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-03-31¥621m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-03-31−¥1.3bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 339
ItemContextValueUnit
Number of shares held in own name treasury shares etcCurrentQuarterInstant561100
Number of shares held in others names treasury shares etcCurrentQuarterInstant－
Total number of shares held treasury shares etcCurrentQuarterInstant561100
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0127
Cash and depositsPrior1YearInstant3105000000JPY
Cash and depositsCurrentQuarterInstant3117000000JPY
Notes and accounts receivable tradePrior1YearInstant1798000000JPY
Notes and accounts receivable tradeCurrentQuarterInstant1744000000JPY
Short term investment securitiesPrior1YearInstant400000000JPY
Short term investment securitiesCurrentQuarterInstant－JPY
Merchandise and finished goodsPrior1YearInstant696000000JPY
Merchandise and finished goodsCurrentQuarterInstant723000000JPY
Work in processPrior1YearInstant598000000JPY
Work in processCurrentQuarterInstant644000000JPY
Raw materials and suppliesPrior1YearInstant658000000JPY
Raw materials and suppliesCurrentQuarterInstant616000000JPY
Other caPrior1YearInstant299000000JPY
Other caCurrentQuarterInstant260000000JPY
Current assetsPrior1YearInstant7556000000JPY
Current assetsCurrentQuarterInstant7106000000JPY
Buildings and structures netPrior1YearInstant2234000000JPY
Buildings and structures netCurrentQuarterInstant2181000000JPY
Machinery equipment and vehicles netPrior1YearInstant2044000000JPY
Machinery equipment and vehicles netCurrentQuarterInstant1965000000JPY
LandPrior1YearInstant1807000000JPY
LandCurrentQuarterInstant1818000000JPY
Construction in progressPrior1YearInstant6000000JPY
Construction in progressCurrentQuarterInstant5000000JPY
Other net ppePrior1YearInstant303000000JPY
Other net ppeCurrentQuarterInstant283000000JPY
Property plant and equipmentPrior1YearInstant6397000000JPY
Property plant and equipmentCurrentQuarterInstant6255000000JPY
Intangible assetsPrior1YearInstant222000000JPY
Intangible assetsCurrentQuarterInstant199000000JPY
Investment securitiesPrior1YearInstant533000000JPY
Investment securitiesCurrentQuarterInstant533000000JPY
Other ioaPrior1YearInstant336000000JPY
Other ioaCurrentQuarterInstant309000000JPY
Investments and other assetsPrior1YearInstant869000000JPY
Investments and other assetsCurrentQuarterInstant843000000JPY
Noncurrent assetsPrior1YearInstant7489000000JPY
Noncurrent assetsCurrentQuarterInstant7297000000JPY
AssetsPrior1YearInstant15046000000JPY
AssetsCurrentQuarterInstant14404000000JPY
Notes and accounts payable tradePrior1YearInstant274000000JPY
Notes and accounts payable tradeCurrentQuarterInstant356000000JPY
Current portion of long term loans payablePrior1YearInstant1039000000JPY
Current portion of long term loans payableCurrentQuarterInstant969000000JPY
Accounts payable otherPrior1YearInstant554000000JPY
Accounts payable otherCurrentQuarterInstant414000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2022-01-01/2022-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass